Sibo Jiang
4 Papers
Sibo Jiang is an academic researcher. The author has contributed to research in topics: Internal medicine & Multiple myeloma. The author has an hindex of 1, co-authored 3 publications.
Chat about Author
Papers
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
Nizar J. Bahlis,Caitlin L. Costello,Noopur Raje,Moshe Y Levy,Bhagirathbhai Dholaria,Melhem Solh,Michael H. Tomasson,M Damore,Sibo Jiang,Cynthia Basu,Athanasia Skoura,Edward M. Chan,Suzanne Trudel,Andrzej Jakubowiak,Cristina Gasparetto,Michael P Chu,Andrew P. Dalovisio,Michael Sebag,Alexander M. Lesokhin +18 more
TL;DR: In the first-in-human trial of elranatamab, patients with refractory or relapsed multiple myeloma who received the bispecific antibody against BCMA and CD3 experienced no dose-limiting toxicities during dose escalation, and the agent showed promising clinical efficacy.
50
Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.
Andrzej Jakubowiak,Nizar J. Bahlis,Noopur Raje,Caitlin Costello,Bhagirathbhai Dholaria,Melhem Solh,Moshe Yair Levy,Michael H. Tomasson,Harman Dube,Michael A. Damore,Sibo Jiang,Cynthia Basu,Athanasia Skoura,Edward M. Chan,Suzanne Trudel,Michael P. Chu,Cristina Gasparetto,Andrew P. Dalovisio,Michael Sebag,Alexander M. Lesokhin +19 more
TL;DR: Elranatamab shows a manageable safety profile and achieves durable clinical and molecular responses for patients with relapsed or refractory MM with MagnetisMM-1, the ongoing Phase 1 first-in-human study for elranatams.
13
Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma
Mohamed Elmeliegy,Andrea Viqueira,Erik Vandendries,Anne Hickman,Jennifer E. Hibma,Hoi-Kei Lon,Joseph Piscitelli,Pooneh Soltantabar,Diane Wang,Sibo Jiang,G. Finn,Akos Czibere +11 more
TL;DR: In this article , the authors presented a pooled analysis of CRS across 4 clinical studies leading to the selection and validation of the optimal priming regimen for elranatamab as a 2 step-up priming strategy.
10
Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1.
Michael H. Tomasson,Nizar J. Bahlis,Caitlin Costello,Noopur Raje,Moshe Yair Levy,Bhagirathbhai Dholaria,Melhem Solh,M Damore,Sibo Jiang,Cynthia Basu,Athanasia Skoura,Edward M. Chan,Suzanne Trudel,Andrzej Jakubowiak,Cristina Gasparetto,Michael Chu,Andrew P. Dalovisio,Michael Sebag,Alexander M. Lesokhin +18 more
TL;DR: Elranatamab (PF-06863135), a BCMA x CD3 bispecific antibody, redirects the T-cell mediated immune response against multiple myeloma (MM) as discussed by the authors .